earningsconfidence high
Aura Q1 net loss $33.7M; Phase 3 CoMpass enrollment mid-2026; new CEO appointed
Aura Biosciences, Inc.
2026-Q1 EPS reported
-$0.50
- Net loss of $33.7M in Q1 2026; R&D expenses $28.0M (up from $23.3M) reflecting Phase 3 costs.
- Phase 3 CoMpass trial in early choroidal melanoma enrollment expected to complete mid-2026; topline data in 2H 2027.
- Natalie Holles appointed CEO and President effective April 30, 2026, succeeding founder Elisabet de los Pinos.
- Completed $299M equity offering (net ~$280.8M); used $39M to repurchase shares from Matrix Capital; cash into 2H 2028.
- Pipeline: Phase 2 choroidal metastases data in 2026; Phase 1 ocular cancer PoC data in 2026; bladder cancer data mid-2026.
item 2.02item 8.01item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.